

ASX ANNOUNCEMENT

CELLMID ENGAGES ADVISERS TO FACILITATE DIVESTMENT FROM LYRAMID

Key Highlights

- **Cellmid advised the market in February 2019 of its intention to separate its consumer health and biotech assets**
- **Midkine related biotech assets have since been developed and prepared for divestment in wholly owned subsidiary, Lyramid**
- **Cellmid appointed C14 Consulting and PharmaVentures Limited to actively pursue opportunities for partnering or divestment**

SYDNEY, Thursday, 10 September 2020: Cellmid Limited (ASX: CDY) is pleased to advise that it has appointed C14 Consulting and PharmaVentures Limited to actively search for partners or buyers for Lyramid, Cellmid's wholly owned subsidiary engaged in the research and development of treatments for inflammatory diseases and cancer targeting midkine, an embryonic growth factor implicated in a number of disease indications.

The two agreements are independent from each other and have similar terms including no exclusivity. Under the agreements the only fee payable by Cellmid to either of the consultants will be a success fee on completion of the sale or partnering of the midkine asset portfolio. The reason for signing two agreements is to fully exploit both partnering and divestment options efficiently. The appointments have been made based on the relevant expertise of each consulting firm.

C14 Consulting is the premier business development partner for alliances and partnerships in life sciences and is led by a team of senior business development professionals with experience in large pharmaceutical and biotechnology companies.

PharmaVentures is the global expert in mergers and acquisitions in the life sciences sector having completed more than 1,000 successful assignments over 30 years in 38 countries. Fintan Walton, a non-executive director of Cellmid Limited is the founder and Managing Director of PharmaVentures. For the purposes of section 208 of the Corporations Act the Company considers that the engagement of PharmaVentures was under the "arm's length terms" exception provided by section 210 of the Corporations Act. In forming this view the Company recognized that the terms of the agreement with PharmaVentures are the same as those agreed with non-related C14 Consulting.



Cellmid will be advising the market in due course on any material developments in relation to the divestment program.

Approved for release by the Board of Directors of Cellmid.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid's wholly owned subsidiary, Lynamid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Most recently Cellmid secured access to a range of SARS-CoV-2 antibody and nucleotide tests, both point of care and laboratory based, from various suppliers.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.